- Home
- NFJ vs ANAB Comparison
NFJ vs ANAB Comparison
Compare NFJ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | ANAB |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NFJ | ANAB |
|---|---|---|
| Price | $12.85 | $56.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $74.64 |
| AVG Volume (30 Days) | 216.3K | ★ 635.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $10.02 | $15.40 |
| 52 Week High | $13.92 | $68.39 |
Technical Indicators
Market Signals| Indicator | NFJ | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 43.63 |
| Support Level | $12.42 | $52.68 |
| Resistance Level | $13.14 | $57.70 |
| Average True Range (ATR) | 0.20 | 3.88 |
| MACD | 0.05 | -1.38 |
| Stochastic Oscillator | 64.06 | 12.71 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).